[177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer
- PMID: 30102222
- DOI: 10.1016/S1470-2045(18)30488-1
[177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer
Comment in
-
[177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer - Author's reply.Lancet Oncol. 2018 Aug;19(8):e373. doi: 10.1016/S1470-2045(18)30534-5. Lancet Oncol. 2018. PMID: 30102223 No abstract available.
Comment on
-
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8. Lancet Oncol. 2018. PMID: 29752180 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous